{"id":"metronidazole-vaginal-gel-0-75","safety":{"commonSideEffects":[{"rate":null,"effect":"Vulvovaginal irritation or burning"},{"rate":null,"effect":"Metallic taste"},{"rate":null,"effect":"Vaginal discharge"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL137","moleculeType":"Small molecule","molecularWeight":"171.16"},"_dailymed":{"setId":"63ed1e7e-d264-4e35-af83-ec37fa5b06d1","title":"METRONIDAZOLE VAGINAL GEL, 0.75% (METRONIDAZOLE) GEL [ENCUBE ETHICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a nitroimidazole prodrug that is activated by anaerobic organisms to form reactive intermediates that bind to and cleave bacterial DNA, preventing replication and causing cell death. It is effective against anaerobic bacteria and certain protozoa. The vaginal gel formulation delivers the drug topically to treat local vaginal infections.","oneSentence":"Metronidazole disrupts bacterial DNA by generating reactive oxygen species and damaging microbial genetic material, thereby killing anaerobic bacteria and protozoa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:04.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial vaginosis"},{"name":"Trichomoniasis vaginalis infection"}]},"trialDetails":[{"nctId":"NCT01020396","phase":"PHASE1, PHASE2","title":"Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Bacterial Vaginosis","enrollment":579},{"nctId":"NCT00153517","phase":"PHASE2","title":"Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1999-10","conditions":"Vaginosis, Bacterial, Premature Birth, Birth Weight","enrollment":126},{"nctId":"NCT03091777","phase":"PHASE3","title":"Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Balmoral Medical company","startDate":"2017-03-10","conditions":"Bacterial Vaginosis","enrollment":871},{"nctId":"NCT01055106","phase":"PHASE2","title":"Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2010-01","conditions":"Vaginosis, Bacterial, Vaginal Infection","enrollment":255},{"nctId":"NCT01020877","phase":"PHASE1","title":"Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-11","conditions":"Healthy","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Metronidazole Vaginal Gel 0.75%","genericName":"Metronidazole Vaginal Gel 0.75%","companyName":"Balmoral Medical company","companyId":"balmoral-medical-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metronidazole disrupts bacterial DNA by generating reactive oxygen species and damaging microbial genetic material, killing anaerobic bacteria and protozoa. Used for Bacterial vaginosis, Trichomoniasis vaginalis infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}